BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 10618709)

  • 1. The role of the E6-p53 interaction in the molecular pathogenesis of HPV.
    Thomas M; Pim D; Banks L
    Oncogene; 1999 Dec; 18(53):7690-700. PubMed ID: 10618709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth.
    Pim D; Massimi P; Banks L
    Oncogene; 1997 Jul; 15(3):257-64. PubMed ID: 9233760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.
    Mantovani F; Banks L
    Oncogene; 1999 Jun; 18(22):3309-15. PubMed ID: 10362351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6.
    Pim D; Banks L
    Oncogene; 1999 Dec; 18(52):7403-8. PubMed ID: 10602499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of TP53 in Cervical carcinogenesis.
    Tommasino M; Accardi R; Caldeira S; Dong W; Malanchi I; Smet A; Zehbe I
    Hum Mutat; 2003 Mar; 21(3):307-12. PubMed ID: 12619117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HPV 16-E6-mediated degradation of intrinsic p53 is compensated by upregulation of p53 gene expression in normal cervical keratinocytes.
    Kawamata Y; Mitsuhashi A; Unno Y; Kado S; Shino Y; Uesugi K; Eguchi O; Ishii J; Seki K; Sekiya S; Shirasawa H
    Int J Oncol; 2002 Sep; 21(3):561-7. PubMed ID: 12168100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products.
    Münger K; Scheffner M; Huibregtse JM; Howley PM
    Cancer Surv; 1992; 12():197-217. PubMed ID: 1322242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The state of p53 in primary human cervical carcinomas and its effects in human papillomavirus-immortalized human cervical cells.
    Chen TM; Chen CA; Hsieh CY; Chang DY; Chen YH; Defendi V
    Oncogene; 1993 Jun; 8(6):1511-8. PubMed ID: 8389030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro.
    Slebos RJ; Kessis TD; Chen AW; Han SM; Hedrick L; Cho KR
    Virology; 1995 Apr; 208(1):111-20. PubMed ID: 11831691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.
    Hampson L; Kitchener HC; Hampson IN
    Antivir Ther; 2006; 11(6):813-25. PubMed ID: 17310826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin C augments chemotherapeutic response of cervical carcinoma HeLa cells by stabilizing P53.
    Reddy VG; Khanna N; Singh N
    Biochem Biophys Res Commun; 2001 Mar; 282(2):409-15. PubMed ID: 11401473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of HPV oncoproteins and cellular factors in maintenance of hTERT expression in cervical carcinoma cells.
    Jeong Seo E; Jung Kim H; Jae Lee C; Tae Kang H; Seong Hwang E
    Gynecol Oncol; 2004 Jul; 94(1):40-7. PubMed ID: 15262117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A plant lignan, 3'-O-methyl-nordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cells.
    Allen KL; Tschantz DR; Awad KS; Lynch WP; DeLucia AL
    Mol Carcinog; 2007 Jul; 46(7):564-75. PubMed ID: 17393435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
    Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
    Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.
    Storey A; Thomas M; Kalita A; Harwood C; Gardiol D; Mantovani F; Breuer J; Leigh IM; Matlashewski G; Banks L
    Nature; 1998 May; 393(6682):229-34. PubMed ID: 9607760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation.
    Thomas M; Massimi P; Jenkins J; Banks L
    Oncogene; 1995 Jan; 10(2):261-8. PubMed ID: 7838526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6.
    Gu Z; Pim D; Labrecque S; Banks L; Matlashewski G
    Oncogene; 1994 Feb; 9(2):629-33. PubMed ID: 8290274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovirus-mediated transfer of human papillomavirus 16 E6/E7 antisense RNA and induction of apoptosis in cervical cancer.
    Hamada K; Shirakawa T; Gotoh A; Roth JA; Follen M
    Gynecol Oncol; 2006 Dec; 103(3):820-30. PubMed ID: 16908054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of HPV E6 proteins in cellular transformation.
    Huibregtse JM; Beaudenon SL
    Semin Cancer Biol; 1996 Dec; 7(6):317-26. PubMed ID: 9284524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical co-expression of human papillomavirus type 16/18 transforming (E6) oncoprotein and p53 tumour suppressor gene proteins in oesophageal cancer.
    Agarwal SK; Chatterji A; Bhambhani S; Sharma BK
    Indian J Exp Biol; 1998 Jun; 36(6):559-63. PubMed ID: 9731468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.